Shopping Cart
Remove All
Your shopping cart is currently empty
Darglitazone
🥰Excellent
Catalog No. T22708Cas No. 141200-24-0
Alias CP-86325
Darglitazone (CP-86325) is a potent, selective agonist of PPAR-γ with antidiabetic actions. Darglitazone is effective in controlling blood glucose and lipid metabolism.
Darglitazone
🥰Excellent
Purity: 99.76%
Catalog No. T22708Alias CP-86325Cas No. 141200-24-0
Darglitazone (CP-86325) is a potent, selective agonist of PPAR-γ with antidiabetic actions. Darglitazone is effective in controlling blood glucose and lipid metabolism.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $32 | In Stock | In Stock | |
| 5 mg | $53 | In Stock | In Stock | |
| 10 mg | $88 | In Stock | In Stock | |
| 25 mg | $147 | In Stock | In Stock | |
| 50 mg | $221 | In Stock | In Stock | |
| 100 mg | $326 | In Stock | In Stock | |
| 200 mg | $468 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Batch Information
Select Batch
Purity:99.76%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | Darglitazone (CP-86325) is a potent, selective agonist of PPAR-γ with antidiabetic actions. Darglitazone is effective in controlling blood glucose and lipid metabolism. |
| In vitro | Darglitazone (30 μM) stimulated UCP2 gene expression, likely through PPAR-γ, and increased UCP2 mRNA levels in cell lines representing white (3T3-L1 and 3T3-F442A), brown (HIB-1B) adipose tissues, and skeletal muscle (L6) [1]. |
| In vivo | In male diabetic ob/ob mice, Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24?h of recovery. Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult[2]. |
| Synonyms | CP-86325 |
| Molecular Weight | 420.48 |
| Formula | C23H20N2O4S |
| Cas No. | 141200-24-0 |
| Smiles | C(CC(=O)C1=CC=C(CC2SC(=O)NC2=O)C=C1)C=3N=C(OC3C)C4=CC=CC=C4 |
| Relative Density. | 1.306 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (130.8 mM), Sonication is recommended.  Ethanol: ≤ 5 mg/mL, Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2.5 mg/mL (5.95 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Darglitazone | purchase Darglitazone | Darglitazone cost | order Darglitazone | Darglitazone chemical structure | Darglitazone in vivo | Darglitazone in vitro | Darglitazone formula | Darglitazone molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.